AJAmado Jiménez-Ruiz

Amado Jiménez-Ruiz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amado Jiménez-Ruiz has a total of 160 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association Between Ultrasound Diaphragmatic Measurements and Mechanical Ventilation in Patients With Guillain-Barré Syndrome

    by Carlos Javier Moreno-Bernardino, Beatriz Alejandra Ramirez-Mora, Paola Alejandra Álvarez-López, Bryan Escamilla-Velazquez, Kevin Sylvain Herrmann Villatoro, Francisco Javier González López, Carlos Hurtado Delgado, Omar Cardenas-Saenz, Amado Jimenez-Ruiz, Lilia Georgina Aguilar-Parra, et al.

    Background and ObjectivesRespiratory failure is a serious complication in Guillain-Barré syndrome (GBS). Traditional clinical scales have limitations in accurately predicting the need for invasive ...

  • Gunshot-induced carotid artery injury: exploring other determined aetiologies of stroke

    by Victor Aguilar-Fuentes, Naomi Nazareth Becerra-Aguiar, Javier E. Anaya-Ayala, José Luis Ruiz-Sandoval, Amado Jiménez-Ruiz

    • 12 May 2026
      • Vol. 84  (5) , 1-2
    Open Access

    Progressive multifocal leukoencephalopathy as the initial presentation of leukemia in a chemotherapy-naive patient.

    by Patricia Orozco-Puga, Naomi Nazareth Becerra-Aguiar, César Ibarra-De la Torre, Amado Jiménez-Ruiz, José Luis Ruiz-Sandoval

  • Open Access

    Implementation of a ketogenic diet clinic in Mexico: A pilot program in a resource-limited setting

    by Melissa Chavez-Castillo, Paloma Hurtado-Cuan, Maria Alejandra Soto-Blanquel, Amado Jimenez-Ruiz, Enrique Gomez-Figueroa, Rosa Marquez-Palacios

  • The Burden of Multiple Sclerosis in Mexico

    by Enrique Gómez-Figueroa, Carlos Javier Moreno-Bernardino, Andrea Margarita De Alba-Sánchez, Natali Guerrero-Udave, Patricia Orozco-Puga, Cynthia Patricia Corona-Vázquez, María Eugeni Briseño-Godínez, Omar Cárdenas-Sáenz, Amado Jímenez-Ruiz, Brenda Allison Verboonen-Salgado, et al.

    Multiple sclerosis (MS) is a CNS disease causing significant disability, mainly in young and middle-aged individuals. Despite extensive global research, Mexico lacks comprehensive epidemiologic data on MS, complicating effective health care planning and intervention. This study analyzes the epidemiology of MS in Mexico using data from the Global Burden of Disease (GBD) study. It focuses on prevalence, incidence, disability-adjusted life years (DALYs), years lived with disability (YLDs), and years of life lost (YLLs) from 1990 to 2021. In addition, it examines the relationship between the sociodemographic index (SDI) and MS burden across Mexican states. Data were sourced from the GBD 2021 and analyzed using standard GBD methodologies. Key metrics included prevalence, DALYs, YLDs, and YLLs, standardized by age. Pearson correlation and linear regression were used to evaluate the association between SDI and MS prevalence. A locally weighted regression (LOESS) model was applied to compare observed and expected DALY rates based on SDI, identifying regional disparities in MS burden. In 2021, an estimated 18,016 individuals (95% uncertainty interval [UI] 14,993-21,337) lived with MS in Mexico, with an age-standardized prevalence of 13.10 per 100,000 inhabitants (95% UI 10.91-15.50). The incidence rate was 0.65 per 100,000 inhabitants (95% UI 0.55-0.75). Total DALYs for MS in 2021 were 17,947 (95% UI 14,458-20,542), comprising 13.05 age-standardized DALYs per 100,000 inhabitants. YLLs accounted for 9.47 per 100,000 inhabitants (95% UI 8.24-10.85) and YLDs for 3.56 (95% UI 2.45-4.77). The LOESS model revealed significant regional discrepancies, with Northern Mexico exhibiting better-than-expected health outcomes while Central and Southern Mexico displaying higher observed DALYs than expected. The findings highlight substantial regional disparities in the MS burden across Mexico. Northern Mexico showed better-than-expected health outcomes while Central and Southern Mexico exhibited higher disease burdens than anticipated. These discrepancies suggest that socioeconomic factors and health care accessibility significantly affect MS outcomes. The study's limitations include reliance on hospital records and potential underdiagnosis in less developed regions. Enhanced data collection and comprehensive health care strategies are essential to effectively address the growing MS burden in Mexico.


  • Pediatric Brain Stem Cavernoma: A Therapeutic Conundrum

    by Naomi Nazareth Becerra-Aguiar, Natali Guerrero-Udave, Oscar Gutierrez-Avila, Jose Luis Ruiz-Sandoval, Amado Jimenez-Ruiz

  • Open Access

    Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry

    by Enrique Gomez-Figueroa, Patricia Orozco-Puga, Cynthia Patricia Corona-Vázquez, Carlos Moreno-Bernardino, Graciela Elizabeth De la Mora-Landín, Amado Jiménez-Ruiz, Christian García-Estrada, Lizeth Zertuche-Ortuño, Sergio Saldívar-Dávila, Roberto Rodríguez-Rivas, et al.

    Background: Switching disease-modifying therapies (DMTs) is common in relapsing-remitting multiple sclerosis (RRMS). Vertical switching to higher-efficacy agents generally outperforms horizontal switching within the same efficacy tier, yet horizontal switches remain frequent where escalation is impractical. Objectives: To compare real-world outcomes after horizontal versus vertical DMT switches and to identify predictors of successful horizontal switching. Design: Retrospective, registry-based observational study. Methods: Adults with RRMS who switched DMTs in the MSBase Registry (2010–2023) were analyzed. Horizontal switches were defined as transitions within efficacy tiers, and vertical switches as transitions to a higher tier. Propensity score matching (1:1) generated balanced cohorts. Multivariable mixed-effects models with a random intercept for patients were used to evaluate associations with outcomes. The primary outcome was no evidence of disease activity (NEDA-3) during the treatment period; secondary outcomes included annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) change, confirmed disability worsening (CDW), confirmed disability improvement (CDI), and progression independent of relapse activity (PIRA). Predictors of successful horizontal switching were explored using logistic regression. Results: A total of 4934 matched switches (2467 pairs) were analyzed. Vertical switching achieved higher NEDA-3 rates than horizontal switching (45.8% vs 33.7%) and was associated with lower ARR, reduced CDW risk, and more frequent CDI; differences in EDSS progression and PIRA were not significant. Among horizontal switchers, 33.7% achieved NEDA-3. Success was associated with lower baseline EDSS, fewer prior relapses, and later-line switching. Outcomes varied by destination therapy: anti-CD20 agents had the highest success (≈50%), followed by cladribine (≈43%) and natalizumab (≈41%), whereas interferon and glatiramer acetate performed the poorest. Switches toward anti-CD20 therapies generally yielded better outcomes than other within-tier changes. Conclusion: Vertical switching should be preferred when treatment modification is required, particularly for patients with active disease. However, a subset of patients can achieve disease stability after horizontal switching, especially those with lower disability and fewer prior relapses. The dynamics of horizontal switching may further influence outcomes, warranting prospective validation.


  • Open Access

    Cerebral Venous Thrombosis Presenting as Simultaneous Intracerebral Hemorrhage

    by Amado Jiménez-Ruiz, Victor Aguilar-Fuentes, Fernando Benavides-Gómez, José Luis Ruiz-Sandoval


  • Contribution of Stroke to Long-Term All-Cause and Cause-Specific Mortality in Mexico City

    by Enrique Gomez-Figueroa, José Luis Ruiz-Sandoval, Andrea Margarita De Alba-Sánchez, Omar Cárdenas-Sáenz, Carlos Zúñiga-Ramírez, Raúl Amavisca-Espinosa, Fátima Macías-Ortiz, Amado Jímenez-Ruiz

    Stroke mortality is more common in low-income and middle-income nations such as Mexico. Prognosis data typically rely on short-term hospital follow-ups, revealing high mortality rates due to systemic complications and early recurrence. We aim to explore stroke's long-term impact by examining all-cause and cause-specific mortality. We analyzed data from the Mexico City Prospective Study (1998-2004) with known mortality outcomes until December 2022. Baseline variables were compared between participants who had stroke and nonstroke participants. Cox proportional hazard regression assessed each variable's contribution to overall mortality. Subsequent analysis within the stroke subgroup aimed to identify unique risk factors of mortality, using Cox regression models adjusted for age, sex, and time since stroke. Among 145,537 eligible participants, 1,492 (1.0%) had a history of stroke. Participants who had stroke were older (57.58 vs 50.16, p < 0.001); had lower mean weekly income ($108.24 vs $176.14, p < 0.001); had higher alcohol intake and smoking frequency; and had more frequent comorbidities such as hypertension (48.9 vs 19.3%, p < 0.001), diabetes (23.4 vs 12.9%, p < 0.001), and ischemic heart disease (5.4 vs 1.0%, p < 0.001). They had a significantly increased risk of death from any cause (hazard ratio [HR] 2.59, 95% CI 2.37-2.83, p < 0.001). Deceased participants with stroke were more likely to be male, with a higher prevalence of diabetes, hypertension, and abnormal waist-hip index. Stroke increased the risk of death from cardiac (HR 3.56, 95% CI 3.02-4.19, p < 0.001), renal (HR 2.05, 95% CI 1.58-2.66, p < 0.001), and pulmonary (HR 2.29, 95% CI 1.79-2.92, p < 0.001) causes. This study confirms stroke's association with higher mortality rates, especially from cardiac, renal, and pulmonary causes in Mexico. It underscores the elevated prevalence of cardiovascular comorbidities and adverse socioeconomic profiles among participants who had stroke and those who died with a history of stroke.


  • Open Access

    Letter to the Editor: Idiopathic Hypertrophic Pachymeningitis presenting as Occipital Neuralgia with associated Chiari Malformation

    by José L Ruiz-Sandoval, Marco A Sánchez-Torres, Jefte Felipe Uribe-Martínez, Amado Jimenez-Ruiz